Cancer diagnostics and precision medicine by NeoGenomics
NeoGenomics stock trades up as streamlined RaDaR ST workflow targets pharma partners
NeoGenomics announced that RaDaR ST offers a streamlined workflow for actionable insights.The company said the solution helps pharma partners monitor therapeutic response with precision. Details ...
NeoGenomics invites engagement on innovation in oncology at USCAP event
NeoGenomics is inviting attendees to visit its booth at the USCAP 115th Annual Meeting, focusing on the latest innovations in precision oncology. The company aims to highlight new developments in ...
NeoGenomics offers preview of booth presence at USCAP2026
NeoGenomics has announced a preview of its booth activities for the upcoming USCAP2026 event, encouraging attendees to visit booth 639 for a firsthand experience of its latest pathology and ...
NeoGenomics unveils high-sensitivity MRD platform for early cancer recurrence detection
NeoGenomics introduces RaDaR ST, a new technology designed to identify minimal residual disease by detecting tumor DNA well before traditional imaging methods can reveal signs of recurrence. The ...
NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping
NeoGenomics will participate in the NextGen Omics Spatial and Data U.S. 2026 event with a special presentation focused on overcoming immunotherapy resistance. The company plans to provide new ...
NeoGenomics launches PanTracer Pro to simplify molecular testing
NeoGenomics has introduced PanTracer Pro, a tool designed to streamline molecular testing into a single order. The launch aims to eliminate the complexity of ordering and ensure patients receive ...
NeoGenomics launches PanTracer Pro for advanced-stage solid tumors
NeoGenomics has announced the launch of PanTracer Pro, a new tool designed to streamline complex molecular testing workflows. This solution aims to assist clinicians in making informed decisions ...
NeoGenomics leverages TSO500 for advanced biopharma insights
NeoGenomics has introduced TSO500 as a comprehensive tool delivering molecular clarity across various stages of therapeutic development. From biomarker discovery to resistance detection, as well ...
NeoGenomics honors Marines with leadership in security efforts
NeoGenomics has recently paid tribute to the United States Marines by highlighting the contributions of Joe Pereira, a retired Marine Corps Major. As the Associate Director of Business ...
NeoGenomics emphasizes cancer testing importance with employee event
NeoGenomics recently held a company picnic at their Global HQ in Fort Myers, FL, to promote awareness about cancer testing solutions and genomic profiling. This initiative reflects the company's ...
NeoGenomics drives momentum at Targets25 with advanced oncology solutions
NeoGenomics is making strides in the field of oncology by presenting their advanced services at the annual Targets25 conference. Focused on accelerating oncology trials through cell therapy, ...
NeoGenomics unveils RaDaR ST at ESMO Congress 2025
NeoGenomics has unveiled its latest MRD solution, RaDaR ST, at the 2025 ESMO Congress. This addition bolsters their pharma services test menu and highlights their commitment to advancing medical ...
NeoGenomics unveils Paletrra revolutionizing spatial proteomics
NeoGenomics has announced the introduction of Paletrra, a groundbreaking spatial proteomics solution. This innovation aims to convert every tissue into deep visual insights, enhancing ...
